Evaluation of the clinical efficacy of anagliptin in type 2 diabetic patients with diabetic nephropathy.

Evaluation of the clinical efficacy of anagliptin in type 2 diabetic patients with diabetic nephropathy. - Evaluation of the clinical efficacy of anagliptin in type 2 diabetic patients with diabetic nephropathy.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012802

Enrollment

Registered

2014-01-09

Start date

2013-10-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes with diabetic nephropathy

Interventions

anagliptin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Type 2 diabetic patients. 2.Outpatients, >= 20 years old (regardless of sex). 3.6.0% <= HbA1c <10.0%. 4.Patients who have not been treated with oral hypoglycemic agents for at least 12 weeks before the study, or patients treated with a stable dose of anti-diabetic medicines, including alpha-glucosidase inhibitors (alpha-GI), biguanide (BG), sulfonylurea (SU) or thiazolidine (TZD) for at least 12 weeks before the study. 5.30 <= urinary albumin/ creatinine ratio (ACR:mg/gCr) < 3000. (stage A2 [microalbuminuria] or A3 [microalbuminuria]) 6.Patients who are able to provide written informed consent.

Exclusion criteria

Exclusion criteria: 1.Patient have been treated with DPP-4 inhibitors within 12 weeks before the study. 2.Patient have been treated with insulins, rapid acting insulin secretagogues, or a high dose of SU (glimepiride > 2mg/day, gliclazide > 40mg/day, glibenclamide > 1.25mg/day). 3.Patient who have a history of allergy to anagliptin. 4.Patients who have severe ketosis, diabetic coma, diabetic pre-coma, or type 1 diabetes 5.Patients who have severe infection,

Design outcomes

Primary

Measure	Time frame
Changes in HbA1c	—

Secondary

Measure	Time frame
1.Lipid profile LDL-C HDL-C TG 2.Renal function ACR (Measurement using a first morning urine sample. Calculation of a geometric average ratio for analysis.) Serum Cr (Calculation of an estimated glomerular filtration rate.) Urine liver fatty acid-binding protein (L-FABP) Serum cystatin C (Cys-C)	—

Countries

Japan

Contacts

Public ContactYuka Kuroshima

Kanazawa Medical University Diabetology and Endocrinology

naipicrc@kanazawa-med.ac.jp076-286-2211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026